Skip to Content

Join the 'Nivolumab' group to help and get support from people like you.

Nivolumab News

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease

Posted 17 Jan 2018 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)-- December 20, 2017 Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.1 The purpose of adjuvant therapy ...

Lung Cancer Drug, Nivolumab (Opdivo), Targets 'Hidden' HIV in French Patient

Posted 1 Dec 2017 by Drugs.com

FRIDAY, Dec. 1, 2017 – In a case that investigators say is a first, a lung cancer drug unmasked and then attacked the kind of HIV-infected cells that standard antiretroviral therapy has been unable to touch. The finding was reported on Dec. 1, which is also World AIDS Day, in the Annals of Oncology. While one AIDS expert said the findings were promising, she noted the drug did not "cure" the ...

Patients' Gut Bugs May Play Role in Cancer Care

Posted 3 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – The type of bacteria that cancer patients harbor in the gut might affect their odds of responding to certain treatments, two early studies hint. The research, in humans and mice, adds to evidence that gut bacteria play a key role in the immune system. But experts stressed it's too soon to make recommendations to cancer patients – including whether they should take ...

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib

Posted 26 Sep 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) September 22, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Approval for this indication has been granted under accelerated ...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment

Posted 2 Aug 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) August 1, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Opdivo (Nivolumab) Offers Some Hope for a Deadly Lung Cancer

Posted 4 Apr 2017 by Drugs.com

TUESDAY, April 4, 2017 – The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo, researchers reported Monday. "For the first time we are ...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

Posted 10 Feb 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)-- February 2, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease ...

Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer

Posted 14 Nov 2016 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2016 --Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.1 ...

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two ...

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of ...

Arthritis Possible Side Effect of Certain Cancer Drugs: Study

Posted 29 Jun 2016 by Drugs.com

TUESDAY, June 28, 2016 – Certain cancer immunotherapy drugs may increase risk for joint and tissue disease, including arthritis, new research suggests. "We keep having referrals coming in from our oncologists as more patients are treated with these drugs," said Dr. Clifton Bingham, director of the Johns Hopkins Arthritis Center in Baltimore. "In particular, as more patients are treated with ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to ...

Opdivo (nivolumab) FDA Approved for the Treatment of Hodgkin Lymphoma

Posted 18 May 2016 by Drugs.com

PRINCETON, N.J., May 17, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head and Neck Cancer, Melanoma - Metastatic, Hepatocellular Carcinoma, Colorectal Cancer, Hodgkin's Lymphoma, Melanoma, Urothelial Carcinoma

Related Drug Support Groups

Opdivo

Nivolumab Patient Information at Drugs.com